Introduction {#S0001}
============

The superfamily of Ras-related Small GTPases regulates a variety of different physiological functions in cells, switching certain pathways on or off in a spatiotemporally controlled manner.^[1](#CIT0001)^ One major subfamily within this superfamily are Rab proteins (Ras-related in brain)^[2](#CIT0002)^ that control vesicular trafficking in eukaryotic cells, including all steps involved from budding of vesicles from a donor membrane, transport along cytoskeletal tracks, and finally tethering and fusion with a target membrane.^[3](#CIT0003),[4](#CIT0004)^

Two interconnected cycles are tightly regulated to allow Rab proteins to fulfill their function: First, Rab proteins are C-terminally modified at one or usually two cysteine residues with geranylgeranyl- moieties, allowing the Rabs to reversibly bind to intracellular membranes.^[5](#CIT0005)^ In addition, a solubilizing factor, the GDP dissociation inhibitor (GDI) can bind prenylated Rab proteins to allow shuttling of the Rab protein through the hydrophilic cytosol.^[6](#CIT0006)^ Second, Rab proteins (like all members of the superfamily) can bind either GDP (guanosine-5'-diphosphate; "off-state") or GTP (guanosine-5'-triphosphate; "on-state"). The cycling between these two states is regulated by additional factors, guanine nucleotide exchange factors (GEFs) that catalyze the GDP-GTP exchange reaction and GTPase activating proteins (GAPs) that accelerate the hydrolysis of bound GTP, thus switching the Rabs on or off, respectively.^[7](#CIT0007)^ Structurally, switching between the active and inactive states is characterized by conformational changes of two important regions within the small GTPases, the switch I and switch II regions, which adopt a mostly disordered state in the GDP-bound form due to loss of interactions with the γ-phosphate group, and an ordered and structurally defined conformation in the active state.^[8](#CIT0008)^

The interconnectivity and mutual dependence of the two cycles of reversible membrane attachment and nucleotide exchange arises from the fact that GDI only binds Rabs in their inactive GDP-bound state with high affinity, but not in their GTP-bound active state.^[9](#CIT0009)^ This leads to a general tendency for Rab proteins to be attached to membranes in their active state, but to be bound to GDI and solubilized in the cytosol in the inactive state.

Finally, in addition to the regulatory factors mentioned above, Rab proteins interact with proteins collectively referred to as "effector" proteins. These proteins are characterized by high specificity toward the conformationally defined active state of Rabs, and not surprisingly, were found to interact with the switch regions of Rab proteins in all structurally characterized Rab:effector complexes.^[10](#CIT0010),[11](#CIT0011)^ In this review, we present an overview of (structurally characterized) Rab:effector complexes with a focus on the binding stoichiometry and multivalent effectors that can bind more than one Rab molecule simultaneously, as well as putative functions thereof.

Rab effectors vary greatly in size and structure {#S0001-S2001}
------------------------------------------------

Several structures of Rab proteins and their effectors have been solved in the past (see overview in [Fig. 1](#F0001) and [Table 1](#T0001)) and it has been shown that structures of different effectors, despite being mostly α-helical, especially within their Rab-binding interfaces, vary greatly both in size and overall domain architecture.^[11](#CIT0011)^ Besides containing (predicted) coiled-coils, Rab effectors usually also contain a variety of additional functional domains, such as domains interacting and modifying cytoskeletal components (e.g. MyoVb and Micals), membrane binding and remodeling motifs (e.g., OCRL, Slac2-a, Rabenosyn-5, EEA1, Fip2) or other Rab/GTPase interaction and regulatory motifs and domains (e.g., GEF and GAP domains in AnkRD27, OCRL and Rab6IP1), and this modular architecture allows them to establish a connection between active GTP-bound Rabs and physiological downstream effects ([Fig. 1](#F0001)). Most effectors characterized so far bind to the Rab proteins via one or two (anti-parallel) helices (e.g., Slac2-a, Slp2-a, Rabenosyn-5, Rabphilin-3a, Rabaptin-5, RILP, etc.), however [Fig. 1](#F0001) also shows several exceptions to this 'rule'. AnkRD27 (VARP) binds Rab32 via 4 parallel helices of its ankyrin repeats,^[12](#CIT0012)^ MyoVb interacts with Rab11a via 3 helices and a loop,^[13](#CIT0013)^ EEA1 binds Rab5 via a short β-hairpin and an α-helix^[14](#CIT0014)^ and OCRL binds to Rab8 via an Immunoglobulin-like β-strand domain and an α-helix.^[15](#CIT0015)^ 10.1080/21541248.2016.1265700-F0001Figure 1.Structurally characterized Rab:effector complexes. The structures of several Rab:effector complexes are indicated together with a scheme showing the overall domain architecture of the effector proteins (according to the SMART and uniprot databases^[42](#CIT0042),[43](#CIT0043)^). The structurally resolved regions involved in Rab-binding are highlighted by a green line including the corresponding pdb code, additional Rab-binding sites/regions are indicated by a black line including the Rab proteins known to bind at the corresponding site (the additional Rab binding sites in MyoVb are inferred from studies on MyoVa^[37](#CIT0037)^). Structures of the Rab:effector complexes are shown in cartoon style (Rab: gray with switch I in red and switch II in blue; effector: green). Besides the Rab-binding regions, Rab effectors usually contain several additional domains, as indicated (bMERB -- bivalent Mical/EHBP Rab-binding domain; C2 -- C2 Ca^2+^-binding domain; CC -- (predicted) coiled-coil regions; CH -- calponin-homology domain; DENN -- Rab GEF domain (uD -- upstream DENN, dD -- downstream DENN); DIL -- Dilute domain; FYVE -- FYVE Zinc finger domain; GRIP - golgin-97, RanBP2α, Imh1p and p230/golgin-245 (Golgi targeting) domain; IPPc - Inositol polyphosphate phosphatase; IQ -- IQ Calmodulin-binding motif; LIM -- Zinc-binding domain (Lin-11, Isl-1, Mec-3); MO -- Monooxygenase domain; PLAT -- Polycystin-1, Lipoxygenase, α-Toxin domain; RUN -- RUN domain; Vps9 -- Vps9 GEF domain; Zn -- Zinc finger C2H2 domain). 10.1080/21541248.2016.1265700-T0001Table 1.Structurally characterized Rab:effector complexes.Rab: effector complexstoichiometrypdb idK~D~referencesRab3a: Rabphilin-3a/Exophilin11:11zbd---^[44](#CIT0044)^Rab4: Rabenosyn-5~440--503~1:11z0k6.2 µM^[19](#CIT0019)^Rab5a: EEA11:13mjh2.4 µM^[14](#CIT0014)^Rab6: Rab6IP11:13cwz---^[45](#CIT0045)^Rab8a: OCRL11:13qbt0.9 µM^[15](#CIT0015)^Rab11a: MyoVb1:14lx0254 nM^[13](#CIT0013)^Rab22: Rabenosyn-5~728--784~1:11z0j9.7 µM^[19](#CIT0019)^Rab27a: Slp2-a/Exophilin41:13bc113.4 nM^[46](#CIT0046),[47](#CIT0047)^Rab27a: Slac2-a/Melanophilin1:12zet112 nM^[47](#CIT0047),[48](#CIT0048)^Rab5a: Rababtin-52:21tu3---^[23](#CIT0023)^Rab6: Gcc1852:23bbp2.3 µM^[22](#CIT0022)^Rab7: RILP2:21yhn---^[24](#CIT0024)^Rab11a: Fip22:22 gzh40 nM^[25](#CIT0025),[49](#CIT0049)^Rab32: VARP/AnkRD272:24cym2.5 µM^[12](#CIT0012)^Rab10:Mical-12:15lpn---^[18](#CIT0018)^

The specificity of effector proteins for the active form of Rab proteins can be explained by the fact that they interact with the conformationally defined switch and interswitch regions of GTP-bound Rabs. Several interactions between amino acids located in these regions and the effector are highly conserved between different Rab:effector complexes. The interface includes several hydrophobic residues (among which is a conserved aromatic triad consisting of Trp, Phe and Phe/Tyr within the interswitch and switch II regions) that are also shared by Arf GTPases.^[7](#CIT0007),[16](#CIT0016)^ The specificity toward certain Rabs or Rab families on the other hand is obtained by interactions of the effectors with stretches of amino acids known as RabSF motifs 1--4 or CDRs (complementarity-determining regions) that differ strongly between different Rab families.^[16](#CIT0016)^

Several reviews^[11](#CIT0011),[16](#CIT0016),[17](#CIT0017)^ give a more extensive overview of Rab:effector interactions and the reader is referred to these for further information.

Multivalency in Rab effectors and its functions {#S0001-S2002}
-----------------------------------------------

Whereas some Rab effectors contain only a single Rab-binding site, several others are known to contain two or even more (different) binding sites ([Table 2](#T0002)) or to dimerize and thus allow binding of two Rabs to similar or identical binding sites within the dimeric effectors (structurally characterized Rab:effector complexes are shown in [Fig. 1](#F0001) including representatives of all cases mentioned above). With respect to the stoichiometry of Rab:effector interactions, the recently published bMERB domains are the first known examples of Rab effectors that provide two separate binding sites within a single domain, and due to their high similarity, the sites have been suggested to have evolved by gene duplication.^[18](#CIT0018)^ Another example of Rab effectors that presumably originated from gene duplication are the two separate Rab-binding sites in Rabenosyn-5 (pdb ids 1z0k and 1z0j) that share a very similar relative orientation toward their bound Rab molecules ([Fig. 1](#F0001)).^[19](#CIT0019),[20](#CIT0020)^ Similar to the case in bMERB domains, the sequences have diverged and two Rab binding sites have been obtained in Rabenosyn-5 with similar overall structure, but different Rab specificity.^[20](#CIT0020)^ However, in contrast to bMERB domains, the Rab binding sites are separated by a linker in Rabenosyn-5 and thus form two separate Rab binding domains (in addition to the two structurally characterized Rab binding sites, Rabenosyn-5 contains a third Rab5 binding site at the N-terminal Zn^2+^ finger domain^[21](#CIT0021)^). 10.1080/21541248.2016.1265700-T0002Table 2.Multivalent Rab effectors.EffectorRabs (No. of sites)referencebMERB domainsRab1, Rab8, Rab10, Rab13, Rab15, Rab35 (2 sites within 1 domain)^[18](#CIT0018)^dGcc88Rab6, Rab19, Rab30 (2 sites)^[29](#CIT0029)^dGolgin-97Rab6, Rab19, Rab30 (3 sites)^[29](#CIT0029)^Gcc185Rab1a, Rab1b, Rab35, Rab6a, Rab6b, Rab9a, Rab9b, Rab15, Rab27b, Rab30, Rab33b, Rab35, Rab36 (5--6 sites)^[22](#CIT0022),[26](#CIT0026)^MyosinVaRab3, Rab6, Rab8, Rab10, Rab11, Rab14, Rab39b (3 sites)^[37](#CIT0037)^Rab6IP1Rab6 and Rab11^[33](#CIT0033)^Rabip4'Rab4 and Rab5 (2 sites)^[32](#CIT0032)^Rabenosyn-5Rab4 and Rab5 (2 sites)^[31](#CIT0031)^

The observation that many effectors form dimers and thus establish two separate (but identical) binding sites (e.g., Rabaptin-5, Gcc185, RILP, Fip2, AnkRD27)^[12](#CIT0012),[22](#CIT0022)-[25](#CIT0025)^ and the presence of (non-identical) Rab-binding sites in multiple separate domains (e.g., Gcc185, Rabenosyn-5)^[19](#CIT0019),[26](#CIT0026)^ or in one single domain (e.g., Micals, EHBPs)^[18](#CIT0018)^ argues for specific functions of this multivalency. One possible function of this multivalency might be that it contributes to a stabilization of active Rabs in complex with their effectors at membranes by simply multiplying the number of membrane-anchored isoprenoids within the complex.^[27](#CIT0027)^ In this case, formation of effector dimers with two identical binding sites is sufficient, but several other functions can be envisaged that would benefit from or would only be possible if two non-identical Rab binding sites were present. Such multivalent effectors could, for example, assist in the formation of Rab microdomains, small membrane areas with high local concentrations of a certain Rab protein ([Fig. 2](#F0002)).^[3](#CIT0003),[28](#CIT0028)^ The idea behind this is that activated Rabs could bind to a multivalent effector protein, which subsequently binds and recruits a second (and depending on the number of available Rab-binding sites a third or fourth) Rab molecule. In a dynamic equilibrium and depending on the association and dissociation kinetics of the Rab:effector complexes, a certain number of Rab proteins would again dissociate and be available to bind another effector molecule, and this would finally lead to an effective clustering of Rabs and effectors at a certain site on the membrane ([Fig. 2B](#F0002)). The availability of two different sites would facilitate this, since one high affinity site could be available for the initial recruitment and stabilization of the effector at a certain membrane domain whereas a second lower affinity site would allow for the necessary dynamics of recruitment and release. 10.1080/21541248.2016.1265700-F0002Figure 2.Structure and putative functions of bMERB domains. (A) The X-ray crystallographic structure of Mical-1 in complex with Rab10 revealed two separate Rab binding sites (additional biochemical characterization showed that the binding sites have different affinities to Rab proteins and the corresponding low and high affinity binding sites at the N- and C-terminus, respectively, are indicated).^[18](#CIT0018)^ (B) Putative functions of bMERB domains are illustrated. These include the release of auto-inhibition by competitive replacement of the auto-inhibitory interaction due to Rab-binding (I.), sorting of vesicular cargo via different specificities of the two separate Rab-binding sites toward certain Rab proteins and establishment of a connection between different Rab compartments (II.) and finally the formation of Rab microdomains on intracellular membranes (III.).

Of course, the presence of non-identical binding sites not only allows binding of two similar Rabs, but also allows evolution of different specificities and binding of multiple different Rabs to the different binding sites to establish connections between these. Several Golgi-localized proteins such as Gcc185 (which contains 5--6 separate Rab-binding sites with varying specificities, see [Fig. 1](#F0001))^[26](#CIT0026)^ for example have been suggested to function in the stabilization of Golgi stacks via simultaneous interaction with several different Golgi-localized Rab proteins and/or to reach into the cytosol to act as capturing tentacles of Rabs and associated vesicles.^[26](#CIT0026),[29](#CIT0029),[30](#CIT0030)^ In some multivalent effectors, binding to multiple different Rabs simultaneously and/or subsequently might also function to establish connections between trafficking steps regulated by different Rabs, as previously suggested for Rabenosyn-5 and Rabip4' (both linking Rab4 and Rab5^31,32^), Rab6IP1 (linking Rab6 and Rab11^33^) and bMERB domains (connecting Rab8 family members, Arf6 and Rab35^18,34^). In many of these cases, the Rab-binding repertoire, consisting of mostly endosomal Rab proteins, further suggests a possible role in sorting of endocytosed cargo and transport to different destinations within the cell ([Fig. 2B](#F0002)). A similar sorting function can also be envisaged for exocytic trafficking.^[35](#CIT0035),[36](#CIT0036)^ It should also be noted that multivalency in some effectors is not exclusive to Rab proteins, since some have been shown to also bind members of other small GTPase families (e.g., Gcc185 and Mical-L1 interact with members of the Arl and Arf GTPases, respectively)^[21](#CIT0021),[34](#CIT0034)^ Furthermore, previous observations that binding of one small GTPase at one site of an effector can either positively or negatively influence the affinity of another GTPase at a second site in Gcc185 are very interesting, since they would allow for an additional level of allosteric control in regulated Rab and/or general GTPase cascades.^[21](#CIT0021),[22](#CIT0022)^

In addition to providing platforms for the coordinated recruitment of different Rab proteins, multiple binding sites in certain effector proteins could also simply ensure binding to multiple different Rabs due to a conserved function of the effector within different trafficking pathways. In this regard, MyoVa, a molecular motor for vesicular transport, has been shown to contain 3 different Rab-binding sites with varying specificity. Although the exact function of the multiple binding sites is not understood,^[37](#CIT0037)^ this might generally allow binding and transport of vesicles from different origins within the cell, with different Rab proteins attached to their surface.

Yet another putative function of the two separate binding sites specific to bMERB domains comes from the observation that Micals form an intramolecular auto-inhibitory interaction between their CH/LIM domains and the bMERB domain ([Fig. 2B](#F0002)),^[35](#CIT0035),[38](#CIT0038)-[40](#CIT0040)^ suggesting that while one Rab-binding site might have a function for recruitment of the effector protein to a certain membrane, the presumably high concentration of active Rabs at this membrane could subsequently lead to displacement of the auto-inhibitory interaction via competitive binding ([Fig. 2B](#F0002)). This model assumes an overlapping binding interface of one of the Rab sites and the auto-inhibitory intra-molecular interaction. The release of auto-inhibition would subsequently allow Mical proteins to bind to actin and depolymerize actin via their monooxygenase domain ([Fig. 2B](#F0002)).^[41](#CIT0041)^

Conclusions {#S0002}
===========

In many publications on Rabs and their effectors it has been shown that multivalency is a common theme in Rab:effector interactions that can be established either by dimerization of the effector proteins, implying binding of two identical Rab molecules, or the presence of separate Rab binding sites within the effectors. In many cases, binding of separate Rabs presumably functions to establish connections between Rab domains and coordinate subsequent vesicular trafficking steps and sorting of vesicular cargo. However, besides this function several other roles of multivalency can be envisaged, as discussed above. bMERB domains might additionally represent a special case due to the propensity of proteins harboring this domain to form an auto-inhibitory interaction. Further research on the Rab specificity and other proteins or domains interacting with the bMERB domain will presumably shed light on their specific role in vesicular trafficking as well as actin interaction and regulation.
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[^1]: Color versions of one or more of the figures in the article can be found online at [www.tandfonline.com/ksgt](http://www.tandfonline.com/ksgt).
